Qualigen Therapeutics Inc. (QLGN)

Business: Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases.

IPO Date: 24-Jun-2015

Chairman & CEO: Mr. Michael S. Poirier

Pres, Chief Strategy Officer & Director: Ms. Amy S. Broidrick

Listing: NASDAQ: QLGN

Country: United States

Headquarters: Carlsbad, CA

Website: https://www.qualigeninc.com

Market cap: $20.25 Mln

Revenue (TTM): $5.54 Mln

Earnings (TTM): $-18.54 Mln

Cash: $13.61 Mln

Total Debt: $1.64 Mln

Insider's Holding: 11.73%

Liquidity: Low

52 Week range: $0.45 - 3.12

Shares outstanding: 38,795,500

7 Years Aggregate:

• CFO: $-66.50 Mln
• EBITDA: $-82.84 Mln
• Net Profit: $-91.14 Mln